AI assistant
Sending…
Cellectar Biosciences, Inc. — Director's Dealing 2025
Feb 18, 2025
35021_dirs_2025-02-18_e909a0c6-a1db-4afb-8f5c-0d9cfa7cef64.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2025-02-14
Reporting Person: Kolean Chad J (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-14 | Stock option (right to buy) | $0.29 | A | 290000 | Acquired | 2035-02-14 | Common Stock (290000) | Direct |
Footnotes
F1: This option shall vest over a period of three years from February 14, 2025, with 1/3 vesting on the first anniversary of February 14, 2026 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of February 14, 2026.
More from Cellectar Biosciences, Inc.
Regulatory Filings
2026
May 29
Proxy Solicitation & Information Statement
2026
May 28
Proxy Solicitation & Information Statement
2026
May 28
Regulatory Filings
2026
May 19
Regulatory Filings
2026
May 18
Regulatory Filings
2026
May 14
Interim / Quarterly Report
2026
May 14
Regulatory Filings
2026
May 8
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Mar 4